Evox’s exosome platform draws Lilly in potential $1.2B CNS deal

 Evox Therapeutics Ltd. sealed a $1.2 billion collaboration with Eli Lilly and Co., to apply its exosome technology to the doubly difficult task of systemically delivering RNA interference and antisense oligonucleotide drugs, to reach central nervous system targets.